Evidence map›Paper›PMID 31999745›Full record

ArticlePloS one2020

A novel gamma radiation-inactivated sabin-based polio vaccine.

Gregory J Tobin, John K Tobin, Elena K Gaidamakova, Taralyn J Wiggins, Ruth V Bushnell, Wai-Ming Lee, Vera Y Matrosova, Stephen J Dollery, Heather N Meeks, Diana Kouiavskaia and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. mBio · 2025
    Article
  6. The ternary complex of MnProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
  8. Article
  9. A NovelMicroorganisms · 2024
    Article
  10. Article
  11. Review
  12. Irradiated oocysts in combination with inulin adjuvant-induced potent immune responses againstVeterinary research forum : an international quarterly journal · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Gregory J TobinBiological Mimetics, Inc., Frederick, MD, United States of America.
John K TobinBiological Mimetics, Inc., Frederick, MD, United States of America.
Elena K GaidamakovaDepartment of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Taralyn J WigginsBiological Mimetics, Inc., Frederick, MD, United States of America.
Ruth V BushnellBiological Mimetics, Inc., Frederick, MD, United States of America.
Wai-Ming LeeBiological Mimetics, Inc., Frederick, MD, United States of America.
Vera Y MatrosovaDepartment of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Stephen J DolleryBiological Mimetics, Inc., Frederick, MD, United States of America.ORCID 0000-0002-1712-3811
Heather N MeeksDefense Threat Reduction Agency, Ft. Belvoir, VA, United States of America.
Diana KouiavskaiaCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America.
Konstantin ChumakovCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America.
Michael J DalyDepartment of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
Biological Mimetics (United States) · USCenter for Biologics Evaluation and Research · USHenry M. Jackson Foundation · USDefense Threat Reduction Agency · USUniformed Services University of the Health Sciences · US

Funding

Nonclinical Development of an Improved Polio VaccineR44AI120260 · NIAID · BIOLOGICAL MIMETICS, INC. · PI TOBIN, GREGORY JOHN · 2017 to 2024
$4.4M
Development of a New Low-Cost Poliovirus Vaccine (Ir-IPV): Feasibility study with PV-2R43AI120260 · NIAID · BIOLOGICAL MIMETICS, INC. · PI TOBIN, GREGORY JOHN · 2015 to 2015
$225k
NIAID NIH HHS R43 AI120260NIAID NIH HHS R44 AI120260
6 · The paper itself

Abstract

A concerted action on the part of international agencies and national governments has resulted in the near-eradication of poliomyelitis. However, both the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV) have deficiencies which make them suboptimal for use after global eradication. OPV is composed of attenuated Sabin strains and stimulates robust immunity, but may revert to neurovirulent forms in the intestine which can be shed and infect susceptible contacts. The majority of IPV products are manufactured using pathogenic strains inactivated with formalin. Upon eradication, the production of large quantities of pathogenic virus will present an increased biosecurity hazard. A logical ideal endgame vaccine would be an inactivated form of an attenuated strain that could afford protective immunity while safely producing larger numbers of doses per unit of virus stock than current vaccines. We report here the development of an ionizing radiation (IR)-inactivated Sabin-based vaccine using a reconstituted Mn-decapeptide (MDP) antioxidant complex derived from the radioresistant bacterium Deinococcus radiodurans. In bacteria, Mn2+-peptide antioxidants protect proteins from oxidative damage caused by extreme radiation exposure. Here we show for the first time, that MDP can protect immunogenic neutralizing epitopes in picornaviruses. MDP protects epitopes in Polio Virus 1 and 2 Sabin strains (PV1-S and PV2-S, respectively), but viral genomic RNA is not protected during supralethal irradiation. IR-inactivated Sabin viruses stimulated equivalent or improved neutralizing antibody responses in Wistar rats compared to the commercially used IPV products. Our approach reduces the biosecurity risk of the current PV vaccine production method by utilizing the Sabin strains instead of the wild type neurovirulent strains. Additionally, the IR-inactivation approach could provide a simpler, faster and less costly process for producing a more immunogenic IPV. Gamma-irradiation is a well-known method of virus inactivation and this vaccine approach could be adapted to any pathogen of interest.

Indexed as

Gamma RaysAnimalsAntibodies, NeutralizingEnzyme-Linked Immunosorbent AssayGenome, ViralHeLa CellsHumansOxidative StressPeptidesPoliovirusPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralRats, WistarViral ProteinsAntibodies, NeutralizingPeptidesPoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralViral Proteins

Identifiers

PMID31999745
PMCPMC6991977
OpenAlexW3003634797

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.